Autoimmune thyroid events (ATEs) are common side effects after alemtuzumab (ALZ) therapy in patients with multiple sclerosis (MS). Our purpose was to reach more robust evidence on prevalence and outcome of the spectrum of alemtuzumab-induced autoimmune thyroid events in patients with multiple sclerosis.
Alemtuzumab-induced thyroid events in multiple sclerosis. A systematic review and meta-analysis / Scappaticcio, L; Castellana, M; Virili, C; Bellastella, G; Centanni, M; Cannavò, S; Campennì, A; Ruggeri, R M; Giovanella, L; Trimboli, P. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - 43:2(2019), pp. 219-229. [10.1007/s40618-019-01105-7]
Alemtuzumab-induced thyroid events in multiple sclerosis. A systematic review and meta-analysis
Virili, C;Centanni, M;
2019
Abstract
Autoimmune thyroid events (ATEs) are common side effects after alemtuzumab (ALZ) therapy in patients with multiple sclerosis (MS). Our purpose was to reach more robust evidence on prevalence and outcome of the spectrum of alemtuzumab-induced autoimmune thyroid events in patients with multiple sclerosis.| File | Dimensione | Formato | |
|---|---|---|---|
|
Scappaticcio_Alemtuzumab_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
781.25 kB
Formato
Adobe PDF
|
781.25 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
